



8-31-07

152

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/760,091	
	Filing Date	January 16, 2004	
	First Named Inventor	Thomas L. CANTOR	
	Art Unit	1641	
	Examiner Name	C. Cheu	
Total Number of Pages in This Submission	14	Attorney Docket Number	532212000624

**ENCLOSURES (Check all that apply)**

<input checked="" type="checkbox"/> Fee Transmittal Form (1 page plus duplicate) <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): PTO/SB/08a/b Form (4 pages plus duplicate) References (104) Return Receipt Postcard
<b>Remarks</b>  CUSTOMER NO. 25225		


**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	MORRISON & FOERSTER LLP		
Signature			
Printed name	Peng Chen		
Date	August 29, 2007	Reg. No.	43,543

I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EM 058419961 US, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: August 29, 2007

Signature: (Lenay Rogus)



PTO/SB/17 (02-07)

Approved for use through 02/28/2007. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

<b>FEE TRANSMITTAL</b> For FY 2007  <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		<b>Complete if Known</b>		
		Application Number	10/760,091	
		Filing Date	January 16, 2004	
		First Named Inventor	Thomas L. CANTOR	
		Examiner Name	C. Cheu	
TOTAL AMOUNT OF PAYMENT (\$)		180.00	Attorney Docket No.	532212000624

<b>METHOD OF PAYMENT</b> (check all that apply)	
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card
<input type="checkbox"/> Money Order	<input type="checkbox"/> None
<input type="checkbox"/> Other (please identify): _____	
<input checked="" type="checkbox"/> Deposit Account	Deposit Account Number: 03-1952 Deposit Account Name: Morrison & Foerster LLP
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)	
<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments

<b>FEE CALCULATION</b>							
<b>1. BASIC FILING, SEARCH, AND EXAMINATION FEES</b>							
	<b>FILING FEES</b>		<b>SEARCH FEES</b>		<b>EXAMINATION FEES</b>		
		<b>Small Entity</b>		<b>Small Entity</b>		<b>Small Entity</b>	
<b>Application Type</b>	<b>Fee (\$)</b>	<b>Fee (\$)</b>	<b>Fee (\$)</b>	<b>Fee (\$)</b>	<b>Fee (\$)</b>	<b>Fee (\$)</b>	<b>Fees Paid (\$)</b>
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	
<b>2. EXCESS CLAIM FEES</b>							
						<b>Small Entity</b>	
<b>Fee Description</b>						<b>Fee (\$)</b>	<b>Fee (\$)</b>
Each claim over 20 (including Reissues)						50	25
Each independent claim over 3 (including Reissues)						200	100
Multiple dependent claims						360	180
<b>Total Claims</b>		<b>Extra Claims</b>	<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>	<b>Multiple Dependent Claims</b>		
_____ - 20 = _____		x _____	= _____		<b>Fee (\$)</b>		<b>Fee Paid (\$)</b>
HP = highest number of total claims paid for, if greater than 20.							
<b>Indep. Claims</b>		<b>Extra Claims</b>	<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>			
_____ - 3 = _____		x _____	= _____				
HP = highest number of independent claims paid for, if greater than 3.							
<b>3. APPLICATION SIZE FEE</b>							
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
<b>Total Sheets</b>	<b>Extra Sheets</b>	<b>Number of each additional 50 or fraction thereof</b>		<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>		
_____ - 100 = _____	/50	_____ (round up to a whole number) x _____		= _____			
<b>4. OTHER FEE(S)</b>							<b>Fees Paid (\$)</b>
Non-English Specification, \$130 fee (no small entity discount)							
Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement							180.00

<b>SUBMITTED BY</b>			
Signature		Registration No. (Attorney/Agent)	43,543
Name (Print/Type)	Peng Chen	Telephone	(858) 720-5117
		Date	August 28 2007

I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EM 058419961 US, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: August 29, 2007

Signature: *Lenay Rogus*

(Lenay Rogus)

Patent

Docket No. 532212000624

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Patent Application of:  
Thomas L. CANTOR et al.

Serial No.: 10/760,091

Filing Date: January 16, 2004

For: METHODS FOR DIFFERENTIATING  
AND MONITORING PARATHYROID  
AND BONE STATUS RELATED  
DISEASES

Examiner: C. Cheu

Group Art Unit: 1641

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the foreign and non-patent literature documents are also submitted herewith. The Examiner is requested to make these documents of record.

Document numbers 34, 44 and 136 are from the prosecution of Applicants' related application number 10/945,608. Document numbers 35-39 are from the reexamination proceeding of United States Patent Number 6,030,790, having Control Number 90/007,412. Document numbers 40 and 41 are from the prosecution of Applicants' related application number 10/641,780. Document number 42 is from the prosecution of Applicants' related Canadian application. Document number 43 is from the reexamination proceeding of United States Patent Number

sd-384230

08/31/2007 WABDELRI 00000067 031952 10760091

01 FC:1806 180.00 DA

6,689,566, having Control Numbers 90/007,685 and 90/007,732. The present application is a Continuation of United States Patent Number 6,743,590, which is a Continuation-in-Part of United States Patent Number 6,689,566.

Document numbers 45-47 are from the prosecution of Applicants' application number 10/799,476. Document numbers 77 and 78 were cited in application number 10/799,476. Document numbers 48-61 are from the prosecution of Applicants' application number 10/265,276. Document numbers 79-88 were cited in application number 10/265,276. Document numbers 62-72 are from the prosecution of Applicants' application number 10/674,294. Document numbers 73-75 are from the prosecution of Applicants' application number 10/958,541. Document numbers 89-105 were cited in application number 10/958,541. Document number 76 is from the prosecution of Applicants' application number 11/516,912. Document numbers 106-135 were cited in application number 11/516,912.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \_\_\_ is enclosed.
  - ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.

☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.

☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_\_ is enclosed.

☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)


Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 532212000624.

Dated: August 28, 2007

Respectfully submitted,

By   
Peng Chen  
Registration No.: 43,543  
MORRISON & FOERSTER LLP  
12531 High Bluff Drive, Suite 100  
San Diego, California 92130-2040  
(858) 720-5117



ALTERNATIVE TO PTO/SB/08A/B (04/07)

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/760,091
				Filing Date	January 16, 2004
				First Named Inventor	Thomas L. CANTOR
				Art Unit	1641
				Examiner Name	C. Cheu
Sheet	1	of	4	Attorney Docket Number	532212000624

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1.	US-4,086,196	04/1978	Tregear	
	2.	US-4,851,356	07/1989	Canfield et al.	
	3.	US-4,968,669	11/1990	Rosenblatt et al.	
	4.	US-5,026,653	06/1991	Lee et al.	
	5.	US-5,075,218	12/1991	Jette et al.	
	6.	US-5,093,233	03/1992	Rosenblatt et al.	
	7.	US-5,208,041	05/1993	Sindrey	
	8.	US-5,256,543	10/1993	Pouletty et al.	
	9.	US-5,317,010	05/1994	Pang et al.	
	10.	US-5,382,658	01/1995	Kronis et al.	
	11.	US-5,434,246	07/1995	Fukuda et al.	
	12.	US-5,496,801	03/1996	Holthuis et al.	
	13.	US-5,589,452	12/1996	Krstenansky et al.	
	14.	US-5,639,617	06/1997	Bohuon	
	15.	US-5,695,955	12/1997	Krstenansky et al.	
	16.	US-5,723,577	03/1998	Dong	
	17.	US-5,747,456	05/1998	Chorev et al.	
	18.	US-5,783,558	07/1998	Duvos et al.	
	19.	US-5,798,225	08/1998	Krstenansky et al.	
	20.	US-5,807,823	09/1998	Krstenansky et al.	
	21.	US-5,840,831	11/1998	Hamachi et al.	
	22.	US-5,955,264	09/1999	Seed et al.	
	23.	US-5,958,384	09/1999	Holick et al.	
	24.	US-6,124,314	09/2000	Cameron et al.	
	25.	US-6,387,711	05/2002	Sundaram et al.	
	26.	US-6,689,566	02/2004	Cantor et al.	
	27.	US-2003/0171288	09/2003	Andrew et al.	
	28.	US-2004/0067526	04/2004	Cantor	
	29.	US-2005/0069952	03/2005	Cantor et al.	
	30.	US-2005/0170443	08/2005	Cantor	
	31.	US-2005/0202506	09/2005	Cantor	
	32.	US-2007/0098726	05/2007	Cantor et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
	33.	EP-1 151 307	02/2007	Cantor et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

sd-384216

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/760,091
				Filing Date	January 16, 2004
				First Named Inventor	Thomas L. CANTOR
				Art Unit	1641
				Examiner Name	C. Cheu
Sheet	2	of	4	Attorney Docket Number	532212000624

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	34.	Final Office Action from serial number 10/945,608, mailed on May 2, 2007	
	35.	Statement of Substance of Interview Under 37 CFR 1.560(b), from Reexamination Control No. 90/007,412, filed on November 8, 2006	
	36.	Appeal Brief, from Reexamination Control No. 90/007,412, filed on December 11, 2006	
	37.	Examiner's Answer to Appeal Brief, from Reexamination Control No. 90/007,412, filed on February 28, 2007	
	38.	Reply Brief, from Reexamination Control No. 90/007,412, filed on April 30, 2007	
	39.	Request for Oral Hearing, from Reexamination Control No. 90/007,412, filed on April 30, 2007	
	40.	Office Communication, from 10/641,780, mailed on June 12, 2007	
	41.	Statement of Substance of Interview, from 10/641,780, filed on June 29, 2007	
	42.	Office Action from Canadian Patent Application No. 2,360,020, mailed on March 12, 2007	
	43.	Statement of Substance of Interview, from Control No. 90/007,685 and 90/007,732, filed on June 29, 2007	
	44.	Advisory Action from 10/945,608, mailed on July 23, 2007	
	45.	Restriction Requirement from 10/799,476, mailed on January 10, 2007	
	46.	Response to Restriction Requirement from 10/799,476, filed on January 24, 2007	
	47.	Non-Final Office Action from 10/799,476, mailed on April 17, 2007	
	48.	Restriction Requirement from 10/265,276, mailed on August 20, 2004	
	49.	Response to Restriction Requirement from 10/265,276, filed on December 18, 2004	
	50.	Non-Final Office Action from 10/265,276, mailed on January 24, 2005	
	51.	Amendment in Response to Non-Final Office Action from 10/265,276, filed on April 25, 2005	
	52.	Non-Final Office Action from 10/265,276, mailed on June 28, 2005	
	53.	Amendment in Response to Non-Final Office Action from 10/265,276, filed on October 7, 2005	
	54.	Final Rejection from 10/265,276, mailed on January 4, 2006	
	55.	Amendment After Final Action (37 CFR Section 1.116) from 10/265,276, filed on April 4, 2006	
	56.	Advisory Action from 10/265,276, mailed on May 18, 2006	
	57.	Pre-Appeal Brief Request for Review from 10/265,276, filed on June 13, 2006	
	58.	Notice of Panel Decision from Pre-Appeal Brief Review from 10/265,276, mailed on August 4, 2006	
	59.	Non-Final Office Action from 10/265,276, mailed on October 20, 2006	
	60.	Amendment in Response to Non-Final Office Action from 10/265,276, filed on January 19, 2007	
	61.	Final Rejection from 10/265,276, mailed on April 19, 2007	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/760,091		
		Filing Date	January 16, 2004		
		First Named Inventor	Thomas L. CANTOR		
		Art Unit	1641		
		Examiner Name	C. Cheu		
Sheet	3	of	4	Attorney Docket Number	532212000624

62.	Restriction Requirement from 10/674,294, mailed on June 2, 2006	
63.	Response to Restriction Requirement from 10/674,294, filed on June 28, 2006	
64.	Non-Final Office Action from 10/674,294, mailed on September 11, 2006	
65.	Amendment in Response to Non-Final Office Action from 10/674,294, filed on December 13, 2006	
66.	Final Rejection from 10/674,294, mailed on February 15, 2007	
67.	Amendment After Final Action Under 37 CFR 1.116 from 10/674,294, filed on April 13, 2007	
68.	Advisory Action from 10/674,294, mailed on April 27, 2007	
69.	Examiner Interview Summary from 10/674,294, mailed on May 17, 2007	
70.	Amendment After Final Action Under 37 CFR 1.116 from 10/674,294, filed on May 18, 2007	
71.	Substance of Examiner Interview from 10/674,294, filed on June 14, 2007	
72.	Non-Final Office Action from 10/674,294, mailed on June 18, 2007	
73.	Restriction Requirement from 10/958,541, mailed on March 7, 2007	
74.	Response to Restriction Requirement from 10/958,541, filed on April 4, 2007	
75.	Non-Final Office Action from 10/958,541, mailed on August 3, 2007	
76.	Restriction Requirement from 11/516,912, mailed on July 31, 2007	
77.	CANFIELD et al., Endocrinology (1982) 110(5):1555-1563	
78.	MOTTE et al., Journal of Immunology (1987) 138(10):3332-3338	
79.	KURIYAMA et al., Blood Purification (1998) 16:43-48	
80.	MONIER-FAUGERE et al., Journal of the American Society of Nephrology (1999) 11:1093-1099	
81.	NISSONSEN et al., J. Biol. Chem. (1988) 263(26):12866-12871	
82.	PARTHEMORE et al., J. Clin. Endocrinol. Metab. (1978) 47(2):284-289	
83.	PODBESEK et al., Endocrinology (1983) 112:1000-1006	
84.	RICHARDS et al., Clin. Nephrol. (1999) 51(2):126-127	
85.	STAFFORD-JOHNSON et al., J. Comput. Assist. Tomogr. (1998) 22(2):295-299	
86.	STEWART et al., J. Clin. Invest. (1988) 81(2):596-600	
87.	THOMPSON et al., PNAS USA (1988) 85(15):5673-5677	
88.	YATES et al., J. Clin. Invest. (1988) 81(3):932-938	
89.	BHASKARAN and PONNUSWAMY, Int. J. Pept. Protein Res. (1988) 32:242-255	
90.	D'AMOUR et al., Endocrinology (1985) 117:127-134	
91.	D'AMOUR et al., J. Immunoassay (1989) 10:191-205	
92.	DELEAGE and ROUX, Protein Engineering (1987) 1:289-294	
93.	GHILLANI et al., Cancer Res. (1989) 49(23):6845-6851	
94.	HENIKOFF et al., PNAS USA (1992) 89:10915-10919	
95.	HOPP and WOODS, PNAS USA (1981) 78:3824-3828	
96.	JANIN, Nature (1979) 277:491-492	
97.	KYTE and DOOLITTLE, J. Mol. Biol. (1982) 157:105-132	
98.	LEI et al., J. Biol. Chem. (1995) 270(20):1182-1186	
99.	LOVERIDGE et al., Endocrinology (1991) 128(4):1938-1946	
100.	MERRIFIELD et al., Biochemistry (1982) 21:5020	
101.	NIALL et al., PNAS USA (1969) 64:771-778	
102.	RABBANI et al., J. Biol. Chem. (1984) 259:2949-2955	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

sd-384216



Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/760,091
				Filing Date	January 16, 2004
				First Named Inventor	Thomas L. CANTOR
				Art Unit	1641
				Examiner Name	C. Cheu
Sheet	4	of	4	Attorney Docket Number	532212000624

103.	STEVENS et al., Journal of Immunological Methods (1988) 108:271-278	
104.	STRYER, (ed.), Biochemistry 2 <sup>nd</sup> ed., (1981) pp. 13-16	
105.	JANEWAY et al., Immunobiology, 5 <sup>th</sup> ed., Appendix I, pages 624-625	
106.	BERSON et al., J. Clin. Invest. (1956) 35:170-190	
107.	BERSON et al., PNAS USA (1963) 49:613-617	
108.	BROADUS et al., J. Clin. Invest. (1977) 60:771-783	
109.	BROSSARD et al., J. Bone and Miner. Res. (1999) 14:S444	
110.	CANTERBURY et al., J. Clin. Invest. (1975) 55:1245-1253	
111.	DAMBACHER et al., Clinical Science (1979) 57:435-443	
112.	ENDRES et al., Kidney International (1982) 21:132	
113.	FLUECK et al., Proceedings of the 58th American Meeting of the Endocrine Society, June 1976	
114.	FREITAG et al., New England Journal of Medicine (1978) 298:29-32	
115.	GALLAGHER et al., J. Lab. Clin. Med. (1980) 95:373-385	
116.	HABENER and POTTS, New England Journal of Medicine (1978) 299:580-585, 635-644	
117.	KAO et al., Clin. Chem. (1982) 28:69-74	
118.	KEUTMANN et al., Biochemistry (1978) 17:5723-5729	
119.	LAFFERTY, Medicine (1966) 45:247-260	
120.	MALLETTE et al., J. Clin. Endocrinology Metab. (1982) 54:1017-1024	
121.	MALLETTE, Ligand Review (1979) 1:18-19	
122.	NUSSBAUM et al., Clin. Chem. (1988) 33(8):1364-1367	
123.	RAISZ et al., Annals International Medicine (1979) 91:739-740	
124.	RODBARD and HUTT, "Statistical Analysis of Radioimmunoassays and Immunoradiometric (labeled antibody) Assays" in Assays, Radioimmunoassays and Related Procedures in Medicine, Vol. 1, Vienna: International Atomic Energy Agency, Vienna, (1974) pp. 165-192	
125.	RODBARD et al., J. Clin. Endocrinology Metab. (1968) 28:1412-1418	
126.	ROOS et al., J. Clin. Endocrinology and Metab. (1981) 53:709-721	
127.	SEGRE et al., American Journal of Medicine (1974) 56:774-784	
128.	SEGRE et al., Biochemistry (1977) 16:2417-2427	
129.	SEGRE et al., J. Clin. Invest. (1981) 67:439-448	
130.	SEGRE et al., J. Clin. Invest. (1981) 67:449-457	
131.	SEGRE et al., J. Clin. Invest. (1972) 51:3163-3172	
132.	SILVERMAN and YALOW, J. Clin. Invest. (1973) 52:1958-1971	
133.	SLATOPOLSKY et al., Journal of American Society of Nephrology (1999) 10:625A	
134.	TRAVIS, (ed.), "Clinical Radioimmunoassay" in State-of-the-Art Scientific Newsletter, Inc., Anaheim, CA 92803, (1980) pp.13-16	
135.	WOOD et al., J. Clin. Chem. Biochemistry (1980) 18:789-795	
136.	Request for Continued Examination from 10/945,608, filed on August 2, 2007	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

sd-384216